By Laurie Chen SHANGHAI, July 23 (Reuters) - Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, ...
-
-
Recent Updates
- Port of Shanghai targets Singapore, London in maritime push from busiest to best
- Shanghai Gigafactory posts 28.4% H1 delivery growth as China powers Tesla’s record Q2
- Chinese Investment Bill Threatens Mercedes and U.S. Automakers
- US Startups Urge Government to Reconsider Ban on Chinese AI Models
- Chinese Economy Awash with Thriving Private Funds Influx
- China’s Involvement Facing Scrutiny: FCC Ruling Prohibits Sale of Devices from High-Risk Chinese Firms
- AI shortens drug discovery to around 1 year in China, Insilico CEO says
- AI shortens drug discovery to around 1 year in China, Insilico CEO says
- Thailand PM to Build Bridges with Myanmar on Environmental Concerns
- Nvidia CEO Advocates for Open-Source Chinese AI Models Amid Market Turmoil
Blogroll